Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ana P. Gonzalez-Rodriguez, Juan Contesti, Leticia Huergo-Zapico, Alejandro Lopez-Soto, Azahara Fernández-Guizán, Andrea Acebes-Huerta, Ana J. Gonzalez-Huerta, Esther Gonzalez, Carmen Fernandez-Alvarez & Segundo Gonzalez. (2010) Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leukemia & Lymphoma 51:10, pages 1829-1836.
Read now
Read now
U. Eileen Vu, Z. Steven Pavletic, Xiaojun Wang & Shantaram S. Joshi. (2000) Increased Cytotoxicity Against B-Chronic Lymphocytic Leukemia by Cellular Manipulations: Potentials for Therapeutic Use. Leukemia & Lymphoma 39:5-6, pages 573-582.
Read now
Read now
S Sivaraman, P Venugopal, R Ranganathan, CG Deshpande, X Huang, A Jajeh, SA Gregory, T O’Brien & HD Preisler. (2000) Effect of interferon-α on CD20 antigen expression of B–cell chronic lymphocytic leukemia. Cytokines, Cellular & Molecular Therapy 6:2, pages 81-87.
Read now
Read now
A. P. Jewell. (1996) Interferon-Alpha, Bcl-2 Expression and Apoptosis in B-Cell Chronic Lymphocytic Leukemia. Leukemia & Lymphoma 21:1-2, pages 43-47.
Read now
Read now
Articles from other publishers (11)
Ofrat Beyar Katz, Dana Yehudai-Ofir & Tsila Zuckerman. (2023) Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?. Acta Haematologica, pages 1-14.
Crossref
Crossref
Max Yano, John C. Byrd & Natarajan Muthusamy. (2022) Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential. Cancers 14:23, pages 5787.
Crossref
Crossref
Max Yano, Chia Sharpe, J. Rachel Lance, Janani Ravikrishnan, Kevan Zapolnik, Xiaokui Mo, Jennifer A. Woyach, Deepa Sampath, Adam S. Kittai, Sumithira Vasu, Seema Bhat, Kerry A. Rogers, Dean A. Lee, Natarajan Muthusamy & John C. Byrd. (2022) Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy. Blood Advances 6:20, pages 5641-5654.
Crossref
Crossref
Paolo Sportoletti, Filomena De Falco, Beatrice Del Papa, Stefano Baldoni, Valerio Guarente, Andrea Marra, Erica Dorillo, Chiara Rompietti, Francesco Maria Adamo, Loredana Ruggeri, Mauro Di Ianni & Emanuela Rosati. (2021) NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. International Journal of Molecular Sciences 22:13, pages 6665.
Crossref
Crossref
Valentina Griggio, Francesca Perutelli, Chiara Salvetti, Elia Boccellato, Mario Boccadoro, Candida Vitale & Marta Coscia. (2020) Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Frontiers in Immunology 11.
Crossref
Crossref
Diego Sánchez-Martínez, Pilar M. Lanuza, Natalia Gómez, Aura Muntasell, Elisa Cisneros, Manuela Moraru, Gemma Azaceta, Alberto Anel, Luis Martínez-Lostao, Martin Villalba, Luis Palomera, Carlos Vilches, José A. García Marco & Julián Pardo. (2016) Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells. Frontiers in Immunology 7.
Crossref
Crossref
J Wild, B J Schmiedel, A Maurer, S Raab, L Prokop, S Stevanović, D Dörfel, P Schneider & H R Salih. (2015) Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis. Leukemia 29:8, pages 1676-1683.
Crossref
Crossref
Caroline Veuillen, Thérèse Aurran-Schleinitz, Rémy Castellano, Jérôme Rey, Françoise Mallet, Florence Orlanducci, Laurent Pouyet, Sylvaine Just-Landi, Diane Coso, Vadim Ivanov, Xavier Carcopino, Réda Bouabdallah, Yves Collette, Cyril Fauriat & Daniel Olive. (2012) Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy. Journal of Clinical Immunology 32:3, pages 632-646.
Crossref
Crossref
M Le Garff-Tavernier, J Decocq, C de Romeuf, C Parizot, C A Dutertre, E Chapiro, F Davi, P Debré, J F Prost, J L Teillaud, H Merle-Beral & V Vieillard. (2010) Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 25:1, pages 101-109.
Crossref
Crossref
Yibing Xu, Jianwu Li, Gregory D. Ferguson, Frank Mercurio, Gody Khambatta, Lisa Morrison, Antonia Lopez-Girona, Laura G. Corral, David R. Webb, Brydon L. Bennett & Weilin Xie. (2009) Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 114:2, pages 338-345.
Crossref
Crossref
H Guven, M Gilljam, B J Chambers, H G Ljunggren, B Christensson, E Kimby & M S Dilber. (2003) Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia 17:10, pages 1973-1980.
Crossref
Crossref